Form 4: Teva Pharmaceutical Director Perry Nisen Reports Share Transactions
SEC Form 4
Director Perry Nisen reports the vesting and subsequent disposal of restricted share units resulting in the acquisition and disposal of ordinary shares.
Summary
- On June 15, 2024, Perry Nisen, a director of Teva Pharmaceutical Industries Ltd, had restricted share units vest.
- These units converted into 21,108 ordinary shares.
- Simultaneously, Nisen disposed of 21,108 ordinary shares.
- Following these transactions, Nisen directly owns 95,683 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting insider transactions, which carries a neutral sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These filings provide transparency into the trading activities of company insiders.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it represents a routine vesting and disposal of shares by a company director.
Key Dates
| Date | Description |
|---|---|
| 06/15/2023 | Restricted Share Units were granted |
| 06/15/2024 | Restricted Share Units vested and shares were disposed of |
| 06/17/2024 | Date of report filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.